fbpx

News

Lundbeckfonden Ventures News

San Diego – May 20, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular metabolism and energy production. The A round was led by New Enterprise Associates. Other participants in the round include Lundbeckfonden...
Today, on 14 May 2019, an annual shareholders’ meeting was held in BONESUPPORT HOLDING AB. A summary of the resolutions adopted follows below. All resolutions were adopted with the required majority. Resolution on adoption of accounts and allocation of the company’s result The annual shareholders’ meeting resolved to adopt the profit and loss statement and...
New post-hoc subset analysis from positive Phase 3 trial selected as part of the Excellence and Innovation Awards to be presented at SAMBA 2019 Cambridge, UK and Indianapolis, US – 10 May 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that an abstract reporting additional data and analyses from its positive...
Cambridge, UK and Indianapolis, US – 7 May 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, announces that its annual general meeting of shareholders (“AGM”) will be held at 11.00 am...
Lund, Sweden, 08.00 am CET, 2 May 2019 – BONESUPPORT™, listed on Nasdaq Stockholm – BONESUPPORT HOLDING AB (publ) – listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids, today publish the financial report for thean emerging leader in orthobiologics for the management of bone voids, today published...
Lund, Sweden, 08.00 am CET, 25 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids will publish its Q1 2019 Interim Report on Wednesday 2 May 2019 at 08.00 am CET. The Company will hold a conference call and an online presentation on the same day at 10.00 am...
Cambridge, UK and Indianapolis, US – 25 April 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) announces that additional data and analyses from its positive Phase 3 clinical trial of BARHEMSYS® (intravenous amisulpride) as a rescue treatment of established post-operative nausea & vomiting (PONV) will be presented today in a poster at...
Lund, Sweden, 17.30 CET, 24 April 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, today announces that Vikram Johri will leave his role as GM & EVP Commercial Operations Eurow and BONESUPPORT as of today. On an interim basis all positions having reported into the GM & EVP Commercial...
BONESUPPORTs annual report for 2018 is now available as a pdf on the group’s web page, www.bonesupport.com. A PDF-version is also attached to this press release. About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs....
1 2 3 57

Lundbeckfonden Ventures

News

Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases
20. May 2019
BULLETIN FROM THE ANNUAL SHAREHOLDERS’ MEETING IN BONESUPPORT HOLDING AB ON 14 MAY 2019
14. May 2019
Acacia Pharma Group PLC – Acacia Pharma’s BARHEMSYS Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients
10. May 2019